The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 80.00
Bid: 80.70
Ask: 81.30
Change: -0.10 (-0.12%)
Spread: 0.60 (0.743%)
Open: 80.00
High: 80.00
Low: 80.00
Prev. Close: 80.10
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Interim Management Statement 2023

26 Oct 2023 07:00

RNS Number : 3198R
Kerry Group PLC
26 October 2023
 
 

Date: 26 October 2023

LEI: 635400TLVVBNXLFHWC59

 

 

KERRY GROUP

Q3 INTERIM MANAGEMENT STATEMENT 2023

 

Continued volume growth with good margin improvement

 

OVERVIEW

 

> Taste & Nutrition Q3 volume growth of 1.6% and Group Q3 volumes +0.1%

> Overall YTD pricing of 1.3%, with third quarter pricing reflecting deflationary environment

> Group margin expansion of +100 bps in Q3, driven by Taste & Nutrition +130bps

> Dairy Ireland YTD volumes -6.2% with margins also impacted by challenging market conditions

> Full year earnings guidance expected to be at low end of previously stated 1% to 5% constant currency range

> Share buyback programme of ?300m to commence at the beginning of November

 

 

 

Edmond Scanlon, Chief Executive Officer

"We delivered a good overall performance in the period recognising varying conditions across our markets. North America saw good improvement through the third quarter, Europe performed in line with expectations while APMEA continued to deliver strong growth. Our unique positioning in foodservice supported our continued strong growth in the channel.

We made good strategic progress through the period with further footprint expansion and strategic acquisitions, and given the Group's strong balance sheet and cash flow, we are also initiating a share buyback programme.

Taste and Nutrition remains strongly positioned for volume growth and margin expansion while recognising current market conditions, however Dairy Ireland performance continues to be impacted by challenging industry dynamics. Given this context, we expect our constant currency earnings growth to be at the low end of our guidance range".

 

Markets and Performance

Given the prevailing industry dynamics through the period, the overall demand environment remained quite resilient. Customer innovation activity primarily focused on new taste profiles, continued improvements to products' nutritional characteristics, products targeting health need states, and providing more relative value options for consumers.

Group reported revenue in the first nine months of the year decreased by 4.2%, reflecting business volume growth of 0.4%, pricing of 1.3% and a contribution from acquisitions of 1.1%, more than offset by the effect of disposals of 5.1% and adverse translation currency of 1.9%. Group EBITDA margin increased by 10bps as benefits from cost efficiency initiatives and portfolio developments were partially offset by the mathematical impact of passing through overall input cost inflation.

Business Reviews

Taste & Nutrition

Growth driven by continued strong foodservice performance

> Overall volume growth of 1.5% with Q3 growth of 1.6%

> Meat, Snacks and Dairy markets achieved good growth

> Pricing of 3.0% with third quarter pricing of -1.4% reflective of some input cost deflation

> EBITDA margin +20bps (Q3 +130bps) primarily reflected benefits from cost efficiencies and portfolio developments, partially offset by the mathematical impact of passing through overall input cost inflation

Overall volumes in the division remained solid considering customer and industry dynamics. Foodservice achieved high-single digit volume growth driven by ongoing innovation with QSRs and coffee chains on menu enhancement, seasonal products, and back-of-house efficiency solutions. Volumes in the retail channel were impacted by customer inventory management in North America.

Within the division, the Food EUM achieved good volume growth led by Meat, Snacks and Dairy. This was supported by strong performances in savoury and culinary taste solutions, as well as Tastesense® salt and sugar-reduction technologies.

Business volumes in emerging markets increased by 5.1% driven by strong growth in the Middle East.

Within the global Pharma EUM, performance was led by good volume growth in cell nutrition and excipients.

Americas Region

> Overall volumes -1.7% (Q3 -0.9%) with improvement in North America in Q3

> Retail channel saw softer market conditions while foodservice performed well

> Good growth in Snacks and Dairy markets

> LATAM achieved overall growth despite softer Q3 market conditions

Performance in the region reflected strong comparatives and customer inventory reductions particularly across the Beverage, Bakery and Meat markets in the retail channel. Innovation and new launch activity remained strong in many categories despite these dynamics. Foodservice delivered good growth through new taste innovations across menus and back-of-house efficiency solutions, particularly with QSRs and coffee chains.

Overall performance in North America improved through the period, with volumes in the third quarter similar to the prior year. Snacks delivered good growth driven by authentic taste-led innovations across global leaders, emerging brands and private label, while Dairy performed well through taste system innovations. Within the Meat market, we continued to see good launch activity with culinary taste and texture solutions against a backdrop of challenging industry conditions.

LATAM achieved overall growth in the period despite softer market conditions in the third quarter. This growth was driven by Mexico with good performances in the Snacks and Meat markets. 

Europe Region

> Overall volumes +3.7%, with Q3 growth of 2.0% in line with expectations

> Volume growth led by Meat, Snacks and Meals markets

> Growth driven by strong performances in UK and Ireland

The region achieved continued excellent growth in the foodservice channel driven by seasonal products, new menu innovations and ongoing nutritional profile improvements. The retail channel delivered a solid performance in the region considering the significant consumer inflationary environment.

Growth in Meat was driven by culinary taste and texture system launches combined with continued nutritional enhancement innovations. Snacks delivered strong growth through savoury taste and Tastesense® salt reduction technologies, while Meals also achieved strong growth through nutritional enhancements and authentic taste solutions for stocks and broths.

APMEA Region

> Overall volume growth of 7.5% with continued strong Q3 growth of 8.2%

> Volume growth led by Meat, Meals and Dairy markets

> Growth was strong in the Middle East and South Asia Pacific

Growth in the region remained strong through the period, particularly in the foodservice channel and within the Food EUM in the retail channel. Excellent growth was achieved in Meat through local authentic taste and texture solutions, while Meals and Dairy had good growth in taste systems and Tastesense® salt reduction technologies.

Within the region, strong growth was achieved in the Middle East and South Asia Pacific, with good overall performance in China considering market conditions through the period. In the third quarter, the Group completed the acquisition of Greatang¹, which broadens and deepens Kerry's capability and portfolio of local taste solutions in the Chinese market.

¹ Acquired 100% of the share capital of Shanghai Greatang Orchard Food Co., Ltd. 

Dairy Ireland

Performance Impacted by Significant Reduction in Dairy Prices

> Volumes -6.2% (Q3: -12.1%) as challenging industry dynamics persisted

> Pricing -6.5% (Q3: -17.6%) relating to increased deflationary market dynamics across the period

> EBITDA Margin -110bps driven by the significant impact from changes in dairy market prices

Volumes in Dairy Ireland were lower through the period, as input cost dynamics continued to impact overall market demand. Within Dairy Ingredients, volumes principally reflected softer market supply dynamics with prices continuing to reduce through the period. Overall growth in Dairy Consumer Products was led by Kerry's branded cheese ranges and private-label spreads.

Financial Review

At the end of September, the Group's net debt was ?1.8 billion. The Group's consolidated balance sheet remains strong, which will support the continued strategic development of the business.

Share Buyback Programme

Today Kerry has announced it will commence a share buyback programme of up to ?300 million of Kerry Group plc ordinary shares. The buyback is underpinned by the Group's strong balance sheet and cash flow, and aligned to Kerry's Capital Allocation Framework. Kerry will commence the share buyback programme at the beginning of November 2023, and an announcement will be made immediately prior to its formal launch.

Board Changes

The Board has agreed to appoint Dr. Genevieve Berger and Professor Catherine Godson as non-executive directors of the Company with effect from 1 November 2023.

Dr. Berger is a global science leader and during her executive career held roles as the Chief Science Officer at Firmenich International SA as well as the Chief Research & Development Officer and Chief Science Officer at Unilever plc. Dr. Berger is currently a non-executive director of Dassault Systèmes SE and previously served on the boards of Air Liquide SA, Astra Zeneca plc and Smith & Nephew plc.

Professor Godson is the Associate Dean, Research and Innovation at University College Dublin ("UCD") School of Medicine. She has an international reputation in scientific research gained during a long and successful academic career in the US, Switzerland and at UCD. Professor Godson has a broad knowledge across human health and is a global expert on diabetes as well as cardiovascular and kidney diseases. She currently serves on the Irish Research Council and as a Trustee of Barts Charity, London.

Future Prospects

While market conditions remain uncertain, Kerry remains well positioned with a good innovation pipeline.

The Group will continue to manage through the current input cost environment in collaboration with customers. Kerry will continue to develop the business through capital investment and acquisitions aligned to its strategic priorities. Taste and Nutrition is strongly positioned for volume growth and margin expansion; however Dairy Ireland performance continues to be impacted by challenging market conditions. Given this context, the Group expects constant currency adjusted earnings growth to be at the low end of the previously stated 1% to 5% guidance range.

 

Note: Constant currency earnings guidance includes a net dilution of approximately 2% from portfolio developments. Foreign exchange translation is expected to be a headwind of approximately 3% on earnings in the full year based on prevailing rates.

 

Disclaimer: Forward Looking Statements

This Announcement contains forward looking statements which reflect management expectations based on currently available data. However actual results may differ materially from those expressed or implied by these forward looking statements. These forward looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update any forward looking statement, whether as a result of new information, future events or otherwise.

 

CONTACT INFORMATION

 

Investor Relations

 

Marguerite Larkin, Chief Financial Officer

 

+353 66 7182000 | investorrelations@kerry.ie

 

William Lynch, Head of Investor Relations

 

+353 66 7182000 | investorrelations@kerry.ie

Media

Catherine Keogh, Chief Corporate Affairs & Brand Officer

+353 45 930188 | corpaffairs@kerry.com

Website

 

www.kerry.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRNKPBNOBDDPKB
Date   Source Headline
14th May 20247:00 amRNSTransaction in Own Shares
13th May 20247:00 amRNSTransaction in Own Shares
10th May 20247:00 amRNSTransaction in Own Shares
9th May 20247:00 amRNSTransaction in Own Shares
8th May 20247:00 amRNSTransaction in Own Shares
3rd May 202412:10 pmRNSKerry Announces €300m Share Buyback Programme
2nd May 20244:14 pmRNSResult of AGM
2nd May 20247:00 amRNSQ1 Interim Management Statement 2024
1st May 202410:05 amRNSTotal Voting Rights
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 202412:42 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20249:48 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 202411:55 amRNSNotice of AGM
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 202410:30 amRNSAnnual Financial Report
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 202412:42 pmRNSDirector/PDMR Shareholding
7th Mar 202412:39 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.